Table 1 Major clinical trials related to myeloid cells for treatment of COVID-19

From: Myeloid cells in COVID-19 microenvironment

Candidate therapeutic	Target	Phase	Registration number	Initiation time	Status	Principal investigators and their unit	Number of patients	References
Tocilizumab	IL-6	II	NCT04317092	Mar 19, 2020	Active, not recruiting	National Cancer Institute, Naples	402
		III	NCT04356937	Apr 20, 2020	Completed	Massachusetts General Hospital	243	⁸⁸
		IV	NCT04377750	Apr 8, 2020	Recruiting	Hadassah Medical Organization	500
		II	NCT04750317	May 11, 2020	Completed	I.M. Sechenov First Moscow State Medical University	414
		III	NCT05002517	Sep 3, 2020	Active, not recruiting	Asociacion Instituto Biodonostia	60
		III	NCT04409262	June 16, 2020.	Completed	Hoffmann-La Roche	649
		II	NCT04363736	May 5, 2020	Completed	Hoffmann-La Roche	97
		II	NCT04445272	May 22, 2020	Completed	Fundacion SEIMC-GESIDA	495
		III	NCT04320615	Apr 3, 2020	Completed	Hoffmann-La Roche	452
Siltuximab	IL-6	II	NCT04329650	Apr 15, 2020	Recruiting	Judit Pich Martínez, Fundacion Clinic per a la Recerca Biomédica	200
Mavrilimumab	GM-CSF	II	NCT04492514	May 20, 2020	Recruiting	Kristin Hudock	60
		II	NCT04397497	May 22, 2020	Not yet recruiting	Ospedale San Raffaele	50
		II	NCT04399980	May 20, 2020	Completed	The Cleveland Clinic	40	⁸⁹
		II	NCT04463004	Sep 2, 2020	Completed	Virginia Commonwealth University	2	⁸⁹
		II	NCT04447469	Jul 27, 2020	Recruiting	Kiniksa Pharmaceuticals, Ltd.	588
Lenzilumab	GM-CSF	II	NCT04583969	Oct 19, 2020	Recruiting	National Institute of Allergy and Infectious Diseases	400
		III	NCT04534725	Dec 17, 2020	Recruiting	Peter MacCallum Cancer Centre, Australia	2282
Gimsilumab	GM-CSF	II	NCT04351243	Apr 12, 2020	Completed	Kinevant Sciences GmbH	227
Tofacitinib	GM-CSF	II	NCT04750317	May 11, 2020	Completed	I.M. Sechenov First Moscow State Medical University	414
Baricitinib	JAK	III	NCT04970719	Jul 10, 2020	Recruiting	Wasim Md Mohosin Ul Haque, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders	382
		II	NCT04321993	Apr 17, 2020	Recruiting	Lisa Barrett, Nova Scotia Health Authority	800
		III	NCT04401579	May 8, 2020	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	1033	^90,91,92
		III	NCT04421027	Jun 12, 2020	Completed	Eli Lilly and Company	1585	⁹³
Reparixin	CXCR1/2	II	NCT04794803	May 5, 2020	Terminated	Dompé Farmaceutici S.p.A	55
		III	NCT04878055	Feb 14, 2021	Recruiting	Dompé Farmaceutici S.p.A	312
Canakinumab	IL-1β	III	NCT04362813	Apr 30, 2020	Completed	Novartis Pharmaceuticals	454	⁸³^,⁹⁴
		II	NCT04365153	Apr 24, 2020	Completed	The Cleveland Clinic	45
Infliximab	TNF-α	III	NCT04593940	Oct 15, 2020	Recruiting	Daniel Benjamin, Duke University	2160
		II	NCT04425538	June 1, 2020	Completed	National Institutes of Health (NIH)	17

Back to article page

Table 1 Major clinical trials related to myeloid cells for treatment of COVID-19

Search

Quick links